These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24673427)

  • 21. The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men; a focus on combined C2/C4 deficiency.
    Boeckler P; Milea M; Meyer A; Uring-Lambert B; Heid E; Hauptmann G; Cribier B; Lipsker D
    Br J Dermatol; 2005 Feb; 152(2):265-70. PubMed ID: 15727637
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicohistological and immunopathological features of patients with cutaneous lupus erythematosus at tertiary dermatology centre in Malaysia.
    Teh YC; Loo CH; Mohd Ali N; Lim AL; Tan WC
    Clin Exp Dermatol; 2022 Aug; 47(8):1490-1501. PubMed ID: 35315538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
    Francès C; Cosnes A; Duhaut P; Zahr N; Soutou B; Ingen-Housz-Oro S; Bessis D; Chevrant-Breton J; Cordel N; Lipsker D; Costedoat-Chalumeau N
    Arch Dermatol; 2012 Apr; 148(4):479-84. PubMed ID: 22508872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical characteristics of cutaneous lupus erythematosus.
    Szczęch J; Rutka M; Samotij D; Zalewska A; Reich A
    Postepy Dermatol Alergol; 2016 Feb; 33(1):13-7. PubMed ID: 26985173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitamin D and cutaneous lupus erythematosus: effect of vitamin D replacement on disease severity.
    Cutillas-Marco E; Marquina-Vila A; Grant WB; Vilata-Corell JJ; Morales-Suárez-Varela MM
    Lupus; 2014 Jun; 23(7):615-23. PubMed ID: 24503020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
    Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
    J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apoptosis of keratinocytes and serum DNase I activity in patients with cutaneous lupus erythematosus: relationship with clinical and immunoserological parameters.
    Skiljevic D; Bonaci-Nikolic B; Brasanac D; Nikolic M
    J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):523-529. PubMed ID: 27557471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients.
    Wenzel J; Brähler S; Bauer R; Bieber T; Tüting T
    Br J Dermatol; 2005 Jul; 153(1):157-62. PubMed ID: 16029342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional study.
    Samotij D; Szczęch J; Antiga E; Bonciani D; Caproni M; Chasset F; Dańczak-Pazdrowska A; Furukawa F; Hasegawa M; Hashizume H; Ikeda T; Islam A; Kim HJ; Lesiak A; Misery L; Mowla MR; Polańska A; Szepietowski JC; Tsuruta D; Verdelli A; Werth VP; Reich A
    Lupus; 2021 Aug; 30(9):1385-1393. PubMed ID: 34000879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Photoprovocation in cutaneous lupus erythematosus: a multicenter study evaluating a standardized protocol.
    Kuhn A; Wozniacka A; Szepietowski JC; Gläser R; Lehmann P; Haust M; Sysa-Jedrzejowska A; Reich A; Oke V; Hügel R; Calderon C; de Vries DE; Nyberg F
    J Invest Dermatol; 2011 Aug; 131(8):1622-30. PubMed ID: 21593767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The classification and diagnosis of cutaneous lupus erythematosus.
    Kuhn A; Landmann A
    J Autoimmun; 2014; 48-49():14-9. PubMed ID: 24486120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.
    Chasset F; Bouaziz JD; Costedoat-Chalumeau N; Francès C; Arnaud L
    Br J Dermatol; 2017 Jul; 177(1):188-196. PubMed ID: 28112801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-nucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease.
    Souza A; da Silva LM; Oliveira FR; Roselino AM; Louzada-Junior P
    Lupus; 2009 Mar; 18(3):223-9. PubMed ID: 19213860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A quality-of-life study of cutaneous lupus erythematosus.
    Batalla A; García-Doval I; Peón G; de la Torre C
    Actas Dermosifiliogr; 2013 Nov; 104(9):800-6. PubMed ID: 23787361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cutaneous lupus erythematosus: update of therapeutic options part I.
    Kuhn A; Ruland V; Bonsmann G
    J Am Acad Dermatol; 2011 Dec; 65(6):e179-93. PubMed ID: 20739095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on pathogenesis and treatment of CLE.
    Privette ED; Werth VP
    Curr Opin Rheumatol; 2013 Sep; 25(5):584-90. PubMed ID: 23872903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus.
    Gammon B; Hansen C; Costner MI
    J Am Acad Dermatol; 2011 Oct; 65(4):717-721.e2. PubMed ID: 21641078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.
    Cortés-Hernández J; Torres-Salido M; Castro-Marrero J; Vilardell-Tarres M; Ordi-Ros J
    Br J Dermatol; 2012 Mar; 166(3):616-23. PubMed ID: 21999437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.
    Chang AY; Piette EW; Foering KP; Tenhave TR; Okawa J; Werth VP
    Arch Dermatol; 2011 Nov; 147(11):1261-7. PubMed ID: 21768444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists.
    Kushner CJ; Tarazi M; Gaffney RG; Feng R; Ardalan K; Brandling-Bennett HA; Castelo-Soccio L; Chang JC; Chiu YE; Gmuca S; Hunt RD; Kahn PJ; Knight AM; Mehta J; Pearson DR; Treat JR; Wan J; Yeguez AC; Concha JSS; Patel B; Okawa J; Arkin LM; Werth VP
    Br J Dermatol; 2019 Jan; 180(1):165-171. PubMed ID: 30033560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.